NCT07345650

Brief Summary

Atelectasis may be encountered in the patient population aged 18-65 years undergoing elective laparoscopic bariatric surgery under general anesthesia with endotracheal intubation. The aim of this study is to compare oxygenation, postoperative atelectasis, and postoperative respiratory complications between the fixed PEEP application (SP Group) and personalized PEEP application (KP Group). In the SP Group, ventilation will be applied with PEEP = 8 cmH2O, tidal volume = 8 ml/kg, and respiratory rate to maintain EtCO2 between 35-40, and this ventilation mode was maintained throughout the entire surgery. In the KP Group, ventilation was applied with tidal volume = 8 ml/kg, PEEP = 4 cmH2O, and respiratory rate to maintain EtCO2 between 35 -40, and dynamic compliance was noted 1 minute after the onset of pneumoperitoneum at 12 mmHg. Subsequently, the PEEP value wastitrated every 2 minutes by increasing it by 2 cmH2O until the level providing the highest dynamic compliance value is reached. If the dynamic compliance value does not increase in two consecutive measurements, the previous PEEP value was defined as the patient's "personalized PEEP" value, and ventilation was continued with this PEEP value until the end of the surgery. In all patients, arterial blood gas (ABG) was obtained 10 minutes after anesthesia induction, at the 10th and 30th minutes of pneumoperitoneum, and 10 minutes after pneumoperitoneum is terminated.Patients were transferred to the recovery room after anesthesia is discontinued, and arterial blood gas sampling and lung ultrasound was performed at 30 minutes postoperatively. On postoperative day 1, presence of atelectasis was assessed with lung ultrasound, and SpO2 was recorded at 4th, 12th, and 24th hours postoperatively. Within 4 hours postoperatively, patients in need of supplemental oxygen were recorded(SpO2 92% was decided as cut-off value). After the 4th hour, the number of patients requiring supplemental oxygen after the 4th hour was recorded and compared in both groups. Data were collected and recorded using a standardized paper-based data collection form. A power analysis measurement (post-hoc test) is planned to be performed. If the power analysis exceeds 80% between the groups, the study will be terminated. Data collection was completed after reaching the planned number of volunteers. The study results will be evaluated using the SPSS statistical analysis program. Numerical data between groups (SP vs. KP) will be evaluated using the ANOVA test or Kruskal Wallis test, while categorical data will be evaluated using the chi-square test or Fisher exact test. P\<0.05 will be considered statistically significant, and univariate and multivariate analyses will be performed.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
40

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Dec 2024

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2024

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 10, 2025

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

January 7, 2026

Completed
9 days until next milestone

First Posted

Study publicly available on registry

January 16, 2026

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 10, 2026

Completed
Last Updated

January 16, 2026

Status Verified

January 1, 2026

Enrollment Period

11 months

First QC Date

January 7, 2026

Last Update Submit

January 7, 2026

Conditions

Keywords

obesitybariatric surgerypostoperative atelectasisindividualized peep

Outcome Measures

Primary Outcomes (3)

  • LUSS score (lung ultrasound severity score)

    Lung aeration was assessed using the Lung Ultrasound Score (LUS). Each lung was divided into six regions (anterior, lateral, and posterior areas, each subdivided into upper and lower regions), resulting in a total of 12 regions. Each region was scored from 0 to 3 based on ultrasound findings, with higher scores indicating greater loss of lung aeration. The total LUS ranged from 0 to 36.

    6 months

  • compliance in individualized and non-individualized peep group

    Compliance was assessed intraoperatively in both the individualized PEEP group and the non-individualized (fixed PEEP) group.In the individualized PEEP group, PEEP was titrated based on dynamic compliance, and respiratory system compliance was recorded at the PEEP level that yielded the highest dynamic compliance value for each patient.In the non-individualized PEEP group, a predefined fixed PEEP level was applied throughout the procedure, and respiratory system compliance was measured at this fixed PEEP level.

    6 months

  • arterial blood gas analysis

    Arterial blood gas analysis was performed to assess arterial oxygenation. The partial pressure of arterial oxygen (PaO₂) was recorded at predefined intraoperative time points and analyzed to determine significant differences between the individualized PEEP and fixed PEEP groups.

    6 months

Study Arms (2)

SP-standard peep

individuals monitored by standard PEEP

KP-individualized peep

individuals monitored by individualized PEEP

Device: Individualized approach

Interventions

individuals were compared by using of a personalized peep or not

KP-individualized peep

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The study population consisted of adult women and men aged 18 to 65 years who were scheduled for elective laparoscopic bariatric surgery. Eligible participants had an American Society of Anesthesiologists (ASA) physical status of I-III and a body mass index (BMI) greater than 30 kg/m². All participants provided written informed consent prior to enrollment. Patients were excluded if they were younger than 18 years or older than 65 years, were not scheduled for bariatric surgery, had an ASA physical status of IV-V, or a BMI less than 30 kg/m². Additional exclusion criteria included refusal or inability to provide informed consent; a history of chronic obstructive pulmonary disease (COPD) classified as GOLD stage III or IV; severe or uncontrolled bronchial asthma; severe restrictive lung disease; a history of pulmonary metastases or previous thoracic surgery; the requirement for preoperative thoracic drainage; the need for preoperative renal replacement therapy; and congestive heart fail

You may qualify if:

  • Adult women and men aged 18 to 65 years Scheduled for elective laparoscopic bariatric surgery American Society of Anesthesiologists (ASA) physical status I-III Body mass index (BMI) \> 30 kg/m² Provision of written informed consent

You may not qualify if:

  • Age \< 18 years or \> 65 years Not scheduled for bariatric surgery ASA physical status IV-V Body mass index (BMI) \< 30 kg/m² Refusal or inability to provide inHistory of Chronic Obstructive Pulmonary Disease (GOLD III and IV) History of severe/uncontrolled bronchial asthma Severe restrictive lung disease History of pulmonary metastases History of thoracic surgery Requiring preoperative thoracic drainage Requiring preoperative renal replacement therapy Congestive heart failure (NYHA Class III and IV)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Yeditepe University

Istanbul, Atasehir, Turkey (Türkiye)

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

arterial blood gas

MeSH Terms

Conditions

ObesityPulmonary Atelectasis

Condition Hierarchy (Ancestors)

OverweightOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and SymptomsLung DiseasesRespiratory Tract Diseases

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Target Duration
6 Months
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 7, 2026

First Posted

January 16, 2026

Study Start

December 1, 2024

Primary Completion

November 10, 2025

Study Completion

April 10, 2026

Last Updated

January 16, 2026

Record last verified: 2026-01

Locations